<DOC>
	<DOCNO>NCT01236001</DOCNO>
	<brief_summary>Observational study request Belgian Institut National d'Assurance Maladie-Invalidité / Rijksinstituut voor Ziekte-en Invaliditeits Verzekering INAMI/RIZIV : - type patient treat VIMPAT® - VIMPAT® dose - Effect VIMPAT® evolution seizure control - Persistence rate 6 month term treatment duration - Discontinuation rate - Description change epilepsy therapy - Safety tolerability</brief_summary>
	<brief_title>Belgian Drug-utilization Study Evaluate Use VIMPAT® Adjunctive Treatment Partial Onset Seizures Subjects Aged 16 Older</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Lacosamide</mesh_term>
	<criteria>An Institutional Review Board ( IRB ) /Independent Ethics Committee ( IEC ) approve write Informed Consent form Subject/legal representative consider reliable capable adhere medication intake accord judgement investigator Based investigator clinical judgement , subject ' seizure activity uncontrolled current therapy subject ' best interest prescribe antiepileptic drug ( AED ) adjunctive therapy . The choice prescribe VIMPAT® adjunctive therapy make treat investigator The subject age 16 old The subject diagnosis epilepsy partialonset seizure accord label The subject medication history least 3 AED therapy ( lifetime and/or concomitant ) treatment failure : due insufficient efficacy , due significant adverse event Sufficient data clinical situation start VIMPAT® information VIMPAT® dosing present subject 's medical record patient treatment VIMPAT® time enrollment study The subject previously participate study participate clinical trial within last 2 month The subject history chronic alcohol drug abuse within last 6 month The subject medical psychiatric condition , opinion investigator , could jeopardize would compromise subject 's ability participate study The subject know hypersensitivity and/or allergy soya , peanut , component VIMPAT® The subject pregnant lactate The subject know AVblock degree 2 3 The subject expect insufficiently compliant contraception . The subject history suicide attempt , receive professional counseling suicidal ideation , currently experience active suicidal ideation</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Lacosamide</keyword>
	<keyword>Vimpat®</keyword>
</DOC>